Core-Needle Biopsy Effective in Evaluation of Renal Masses

Share this content:
Core-Needle Biopsy Effective in Evaluation of Renal Masses
Core-Needle Biopsy Effective in Evaluation of Renal Masses

THURSDAY, March 10, 2016 (HealthDay News) -- Adding core-needle biopsy to other clinical care may help improve outcomes for some patients with renal cell carcinoma, according to a study scheduled to be presented at the annual meeting of the Society of Abdominal Radiology, held from March 13 to 18 in Waikoloa, Hawaii.

Rosaleen Parsons, M.D., of the Fox Chase Cancer Center in Philadelphia, and colleagues tracked outcomes for patients who collectively underwent 374 renal mass biopsies between 1999 and 2015. Core-needle biopsy was performed in 65 percent of patient biopsies, and 41 percent of those patients also had surgical resection.

According to the researchers, core-needle biopsy led to accurate diagnosis of renal cell carcinoma in 94 percent of patients who had surgery. These biopsies also identified benign tumors in 11 percent of patients who could then receive ongoing monitoring -- instead of unnecessary surgery. However, the researchers did find that renal mass biopsy led to inaccurate classification of tumor stage in 37 percent of patients who had surgery, putting them at risk for under-treatment. Also, 30 percent of patients who had biopsies and then surgery potentially had low-risk tumors.

"Combining renal mass biopsy with additional clinical pathways for the management of renal masses may help minimize over- and under-treatment risks," Parsons said in a news release. "Balancing competing risks is important and should ultimately guide individualized patient care."

Press Release
More Information

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »